



Bayer Roadshow Presentation

November 18, 2019
DZ Bank Equity Conference

Oliver Luckenbach, Senior IR Manager
Peter Dahlhoff, IR Manager



Cautionary Statements Regarding Forward-Looking Information

This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at <http://www.bayer.com/>.

The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Guidance at constant currencies, not including portfolio divestitures if not mentioned differently.



Today's agenda

Q3 2019 Results

Bayer at a glance

Our strategy

Bayer: a compelling investment

Bayer Remains on Track - Good Performance Across all Divisions

(all figures: continuing operations)

€9,830m

Sales

€2,291

EBITDA
Before special items

€1.16

Core EPS

€1,263m

Free Cash Flow

- Sales increased to €9.8bn (+5% cpa)
- EBITDA before special items improved by 8% to €2.3bn
→ Margin up 30 bps to 23.3%
- Core EPS plus 6% to €1.16
- Free Cash Flow grew by 13% to €1.3bn

Progress in all Focus Areas

1 *Target Delivery*

- Guidance for 2019 confirmed and adjusted for discontinued operations and Fx

2 *Crop Science*

- Good operational performance in challenging market environment
- Integration and synergy realization well on track

3 *Pharmaceuticals*

- Continued strong top-line growth
- Margin development in line with FY guidance

4 *Consumer Health*

- Solid sales and margin development

5 *Efficiency / Bayer 2022*

- Overall contribution target of ~€2.6bn by 2022 confirmed
- Implementation ongoing

6 *Portfolio Measures*

- Coppertone and Derma Rx divestments closed, Dr. Scholl's and Currenta closings imminent
- Sale of Animal Health signed

Update Glyphosate Litigation

Served lawsuits from approx. 42,700 plaintiffs (as of October 11, 2019)

Number of lawsuits not indicative of the merits of the litigation

Rise in number of plaintiffs follows an exponential increase in advertising sponsored by plaintiffs' lawyers*

Appeals in the first three cases ongoing




Planning for litigation of further cases in 2020 while ...

... constructively engaging in the mediation process

* Source: Based on Roundup TV advertising data provided by X Ante, a litigation advertising tracking service



Crop Science with Positive Growth Dynamics






- +5% cpa (+6% ca pro forma) sales growth driven by North & Latin America
- Good growth across corn and soybean seed & traits as well as fungicides
- Strong increase in EBITDA before special items as a result of higher prices and volumes in Latin America as well as lower than expected product returns
- Cost synergy realization in 2019 substantially higher than expected

● EBITDA Margin before special items



Pharmaceuticals Driven by Xarelto, Eylea and China



- Xarelto up 9%, Eylea grew by 16%
- Continued strong performance in China
- FDA approvals of Nubeqa (darolutamide) and the medically ill indication for Xarelto
- Vitrakvi received first tumor-agnostic approval in Europe
- Acquisition of BlueRock Therapeutics to expand position in cell therapy
- Strong EBITDA before special items as Q3 2018 benefited from opt-in payment of ~€190m


● EBITDA Margin before special items



Consumer Health with Solid Performance

Sales

In million €, Δ% yoy, Fx & portfolio adj.



Volume

+2%

Currency

+1%

Price


+2%

Portfolio

-5%

EBITDA

In million €, Δ% yoy, before special items



- EMEA and Latin America with positive development
- North America and Asia/Pacific with declining sales
- Nutritionals, Allergy & Cold and Pain & Cardio with good sales growth
- Increase in EBITDA-margin before special items driven by sales growth and cost savings

● EBITDA Margin before special items




Q3 Results (Continuing Operations)

Sales

In million €, Δ% yoy, (Fx & portfolio adj.)


- Positive Fx effect of €215m



EBITDA

In million €, before special items


- Positive Fx effect of €77m after hedging



Core EPS

In €


- Core financial result went from minus €497m to minus €455m
- Core tax rate was 18.3% (PY 14.2%)



Free Cash Flow

In million €


- Increase driven by positive operating development



● EBITDA Margin before special items



Bridge: Core EPS to EPS (Q3 2019)





Bayer Delivers on Announced Portfolio Measures

Animal Health

CURRENTA
Leistung für Chemie und Industrie

Coppertone


Dr.Scholl's

Sales & EBITDA*	// Sales: €1,501m // EBITDA: €358m	// Sales: €1,344m // EBITDA: €220m	// Sales: 213m USD // Below average margin	// Sales: 234m USD // Below average margin
Gross Proceeds	// US\$7.6bn, thereof // US\$5.3bn in cash and // US\$2.3bn in Elanco stock**	// ~€1.4bn (60% stake and selected real estate)	// US\$550m	// US\$585m
Acquirer	// Elanco	// Macquarie Infrastructure and Real Assets (MIRA)	// Beiersdorf	// Yellow Wood Partners
Signing	// August 20, 2019 ✓	// August 6, 2019 ✓	// May 13, 2019 ✓	// July 19, 2019 ✓
Expected Closing	// Mid 2020	// December 2019	// Closed on August 30, 2019 ✓	// November 2019
Consolidation	// Discontinued operations	// Discontinued operations	// Until closing	// Until closing

* EBITDA = EBITDA before special items

** based on the unaffected 30-day volume weighted average price as of August 6, 2019 of 33,60 USD. The number of shares constituting the equity consideration is fixed within a 7.5% collar. This means that the number of Elanco shares that Bayer receives increases (decreases) in the event of share price decreases (increases) within this 7.5% corridor. Based on the closing price of Elanco shares on September 30, 2019, Bayer would receive approx. 73 million Elanco shares.

Net Financial Debt Reduced to €37.9bn in Q3



// ~60% of financial debt denominated in US\$

// ±1% change of US\$ vs € = ±€200m

* Excluding divestment proceeds

Key Initiatives for Q4 2019

Crop Science: Expect continued growth in Latin America and a strong start to the US season; continued momentum in achieving integration synergies

Pharmaceuticals: Continuing strong growth of Xarelto, Eylea and China

Consumer Health: Further driving turnaround and expect North America to return to growth

Continued cost and cash management discipline across the Group

Cash-in from Currenta & Dr. Scholl's divestments



FY 2019 Guidance Confirmed, Aligned to Continuing Operations and Including Expected Currency Impact

	Excluding currency impact				
	2019 outlook confirmed (excl. portfolio measures)	Of which discontinued operations	2019 outlook for continuing operations	Expected currency impact	2019 outlook for continuing operations incl. currency impact
Sales	~ €46 bn ✓	~ €3bn	~ €43 bn	approx. +€0.5bn	~ €43.5 bn
EBITDA (before special items)	~ €12.2 bn ✓	~ €0.6bn	~ €11.6 bn	approx. -€0.1bn	~ €11.5 bn
Core EPS	~ €6.80 ✓	~ €0.35	~ €6.45	approx. -€0.10	~ €6.35
Free cash flow	~ €3-4 bn ✓	No impact	~ €3-4 bn	approx. -€0.1bn	~ €3-4 bn
Net financial debt	~ €36 bn ✓	~ €2.0bn Proceeds from the sale of Coppertone, Dr. Scholl's and Currenta	~ €34 bn	approx. +€1.1bn	~ €35 bn

Focus Areas

1

Target Delivery

- Deliver on operational targets

2

Crop Science

- Integration of acquired business to shape the future of agriculture

3

Pharmaceuticals

- Deliver sales and margin expansion
- Further strengthening of pipeline and intensify external sourcing

4

Consumer Health

- Drive performance improvement

5

Efficiency / Bayer 2022

- Execute efficiency improvement program and realize synergies

6

Portfolio Measures

- Finalize remaining portfolio measures



Today's agenda

◆ Q3 2019 Results

◆ **Bayer at a glance**

◆ Our strategy

◆ **Bayer: a compelling investment**



We are a Global Leader in Health and Nutrition





Purpose:
Science For A Better Life
We leverage science to address urgent societal needs – with the ultimate goal to *improve people's lives*




We Address Megatrends Which Impact Lives Across the Globe

Megatrends through 2050


Aging population



Growing population



Pressure on ecosystems



¹ World Population Prospects: The 2017 Revision | ² FAO 2017, (FAO Global Perspective Studies) | ³ FAOSTAT (accessed Oct 30, 2018) for 1961-2016 data on land, FAO 2012 for 2030 and 2050 data on land, and UNDEDA 2017: World Population Prospects for world population data | ⁴ Nelson et. al, (2014); FAO 2016 "Climate change and food security"



We are a Major Global Player with Broad Geographical Presence

All figures as of FY 2018

€ **39.6**bn

Sales

Fx & portfolio adj.

€ **9.6**bn

EBITDA

Before special items

117k

Employees

32.000 of which in Germany

90

Countries

with local Bayer presence

€ **4.7**bn


Free cash flow

€ **5.2**bn

R&D Investments

Expense ratio of 13.3% with regard to sales

Sales by region¹



¹Monsanto only included since June 7th, 2018



We Have Three Strong Segments in Health and Nutrition

#1

Position



Crop Science

- Growing ahead of competition over last five years on average
- Best-in-class profitability through the cycle
- Leading portfolio of seeds & traits, crop protection and digital farming

Leading positions

in key therapeutic areas



Pharmaceuticals

- One of the fastest growing Pharma businesses over the past five years
- Xarelto and Eylea among the world's leading Pharma brands
- Innovative medicines in areas of high unmet medical need

#2

Position



Consumer Health


- Leading positions in 7 of the Top 10 OTC markets
- Portfolio of 14 trusted iconic brands with >€100m revenue
- Branded self-care solutions that help transform people's daily health



Strong Businesses Contributed to Sales and Earnings Growth in 2018


Sales by segment

Fx & portfolio adj., in 2018



EBITDA by segment

Before special items in 2018




Commentary

- **Crop Science** sales and earnings development reflects Monsanto contribution since June 2018
- **Pharmaceuticals** continued to grow, driven by Xarelto, Eylea and China
- **Consumer Health** with stable sales development – implementation of turnaround plan started




We are Active in Attractive, Innovation-Driven Markets



¹ Pro-forma calculations Bayer, Bayer CS market model | ² excluding potential cyclical recovery of the Crop Science market | ³ IQVIA | ⁴ Market model in-market sales OTC medicines, data from IQVIA, Nicholas Hall



Every Market Has its Own Specific Characteristics






Crop Science: Number One Global Platform

FINANCIALS


Sales development

In €m




EBITDA margin development

In %, before special items



Sales by region (pro-forma)


In %, in 2018



PRODUCTS

Leading product areas (pro-forma)

In %, based on sales 2018



Market positions¹ (pro-forma)



- Corn
- Soybean
- Horticulture
- Cereals
- Digital Farming

Key products



¹ Source: Bayer CS market model




Pharma: Focused on Therapeutic Areas With High Unmet Needs

FINANCIALS


Sales development

In €m




EBITDA margin development

In %, before special items



Sales by region


In %, in 2018



PRODUCTS

Therapeutic areas

In %, based on sales 2018




Leading positions in key therapeutic areas¹



Cardiovascular
Hematology
Retinal Diseases
Women's Health
Radiology

Key products

In €m




¹ Source: IQVIA 2017




Consumer Health: Focus on Five Core OTC Categories

FINANCIALS


Sales development
In €m



EBITDA margin development
In %, before special items




Sales by region
In %, in 2018



PRODUCTS

Categories
In %, based on sales 2018



Market positions¹



Key products



¹ PARS database January 2019



Today's agenda

◆ Q3 2019 Results

◆ Bayer at a glance

◆ **Our strategy**

◆ Bayer: a compelling investment



Four Clear Strategic Priorities to Drive Value Creation



Growth ahead of competition
in health and nutrition



Strong free cash
flow generation



Consistent profitability
enhancement



Disciplined
capital allocation



Good Progress of Bayer 2022 Synergy and Efficiency Programs

GROUP


- ✓ Implementation of Bayer 2022 platform program well on track
 - Annual cost savings of €1.4bn by 2022 confirmed
 - Functional targets defined and translated into granular action plan
 - Consultation with employee representatives started
 - Good response to offered personnel instruments for FTE reduction in Germany

9M 2019


SEGMENTS

- ✓ **Crop Science**
 - Strong progress with integration
 - Synergy capture on track
- ✓ **Pharmaceuticals**
 - Target operating model for realigned R&D defined
 - Focus on disciplined cost management
- ✓ **Consumer Health**
 - Executing on Phase 2 of turnaround plan
 - Reset of cost base well advanced

Outlook 2020




Indicative phasing of contributions





Clear Priorities for Capital Allocation

Targeted free cash flow



Disciplined capital allocation

Shareholder return

- Growing dividends
- Consider share buy backs with parts of divestment proceeds

Deleveraging

- Target range ~€26 – 28bn¹ net financial debt by end 2022

Innovation & acquisitions

- Investment in licensing opportunities
- Potentially selective bolt-on acquisitions

Divestment proceeds



¹ Before M&A / Portfolio



Today's agenda

◆ Q3 2019 Results

◆ Bayer at a glance

◆ Our strategy

◆ **Bayer: a compelling investment**



Bayer: A Compelling Investment





- 1 Global leader in health and nutrition
- 2 Active in highly attractive, growing and profitable markets driven by megatrends
- 3 Focused strategy and ambitious targets for 2022
- 4 Strong deleveraging ability to achieve single-A rating again
- 5 Clear priorities for capital allocation



Appendix



Late-stage Pipeline with Progress in Oncology

	Larotrectinib (Vitrakvi)	Darolutamide (Nubeqa)	Copanlisib (Aliqopa)	Finerenone	Vericiguat
 Indication	// TRK-fusion Cancer	// Prostate Cancer	// Lymphoma	// Diabetic Kidney Disease	// Chronic Heart Failure
 Status	// Launched in the US and EU/ in registration	// Launched in the US (nmCRPC) // Phase III (mHSPC)	// Launched in the US // Phase III	// Phase III	// Phase III (HFrEF) // Phase II (HFpEF)
 Commercial Potential	// PSP >€750m	// PSP ≥€1bn	// PSP ≥€0.5bn	// PSP ≥€1bn	// PSP ~€0.5bn
 Clinical Completion	// Clinical program ongoing	// Completed (ARAMIS, nmCRPC) // Aug 2022e (ARASENS, mHSPC)	// May 2020e (CHRONOS-3) // Sep 2021e (CHRONOS-4)	// Apr 2020e (FIDELIO-DKD) // June 2021e (FIGARO-DKD)	// Completed (VICTORIA, HFrEF) // Nov 2019e (VITALY, HFpEF)

NTRK: Neurotrophic receptor tyrosine kinase; nmCRPC: Non-metastatic castration resistant prostate cancer; mHSPC: Metastatic hormone sensitive prostate cancer; HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; PSP: Peak sales potential